Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
TNDM

TNDM - Tandem Diabetes Care Inc Stock Price, Fair Value and News

45.35USD-0.10 (-0.22%)Market Closed

Market Summary

TNDM
USD45.35-0.10
Market Closed
-0.22%

TNDM Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

TNDM Stock Price

View Fullscreen

TNDM RSI Chart

TNDM Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-20.75

Price/Sales (Trailing)

3.81

EV/EBITDA

-28.25

Price/Free Cashflow

-66.85

TNDM Price/Sales (Trailing)

TNDM Profitability

EBT Margin

-17.68%

Return on Equity

-58.2%

Return on Assets

-15.03%

Free Cashflow Yield

-1.5%

TNDM Fundamentals

TNDM Revenue

Revenue (TTM)

770.0M

Rev. Growth (Yr)

13.16%

Rev. Growth (Qtr)

-2.6%

TNDM Earnings

Earnings (TTM)

-141.5M

Earnings Growth (Yr)

65.52%

Earnings Growth (Qtr)

-42.37%

Breaking Down TNDM Revenue

Last 7 days

-8.3%

Last 30 days

3.1%

Last 90 days

58.8%

Trailing 12 Months

71.6%

How does TNDM drawdown profile look like?

TNDM Financial Health

Current Ratio

3.81

Debt/Equity

1.43

Debt/Cashflow

-0.06

TNDM Investor Care

Buy Backs (1Y)

0.05%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024770.0M000
2023794.7M790.3M771.4M747.7M
2022737.7M765.8M790.7M801.2M
2021541.9M604.8M660.9M702.8M
2020394.2M410.2M439.2M498.8M
2019222.6M281.7M330.1M362.3M
2018115.9M128.7M148.0M183.9M
201783.2M81.5M96.2M107.6M
201680.6M87.9M84.5M84.2M
201554.0M59.4M61.6M72.8M
201431.6M36.3M42.1M49.7M
20139.1M15.7M22.4M29.0M
20120002.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Tandem Diabetes Care Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 11, 2024
allen dick
acquired
-
-
9,396
-
Jun 11, 2024
allen dick
sold
-
-
-9,396
-
Jun 10, 2024
gasser elizabeth anne
acquired
-
-
11,749
evp, chief strategy officer
Jun 10, 2024
gasser elizabeth anne
sold
-
-
-11,749
evp, chief strategy officer
Jun 06, 2024
allen dick
gifted
-97,097
51.32
-1,892
-
May 30, 2024
allen dick
sold
-258,400
51.68
-5,000
-
May 28, 2024
sheridan john f
sold (taxes)
-21,519
51.73
-416
president & ceo
May 28, 2024
morrison susan
sold (taxes)
-6,052
51.73
-117
evp & chief admin. officer
May 28, 2024
leal james
acquired
-
-
310
chief manufacturing officer
May 28, 2024
sheridan john f
acquired
-
-
820
president & ceo

1–10 of 50

Which funds bought or sold TNDM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-3.95
1,432
8,916
-%
May 30, 2024
CAMBRIDGE TRUST CO
unchanged
-
186
1,133
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
124,000
754,000
0.01%
May 24, 2024
Cetera Investment Advisers
new
-
508,381
508,381
-%
May 16, 2024
Beacon Capital Management, LLC
sold off
-100
-4,196
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.06
277,350
2,308,340
-%
May 16, 2024
COMERICA BANK
reduced
-9.67
82,715
1,099,210
-%
May 16, 2024
JANE STREET GROUP, LLC
added
61.57
5,269,150
10,909,800
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
added
62.47
17,633,300
36,293,600
0.02%
May 15, 2024
CITADEL ADVISORS LLC
added
57.21
9,409,990
20,079,900
-%

1–10 of 38

Are Funds Buying or Selling TNDM?

Are funds buying TNDM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TNDM
No. of Funds

Unveiling Tandem Diabetes Care Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
eminence capital, lp
7.9%
5,170,451
SC 13G
Feb 13, 2024
vanguard group inc
10.77%
7,021,906
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
capital world investors
10.0%
6,536,778
SC 13G/A
Jan 23, 2024
blackrock inc.
14.2%
9,259,187
SC 13G/A
Jun 12, 2023
fmr llc
-
0
SC 13G/A
May 10, 2023
capital world investors
10.0%
6,473,192
SC 13G/A
Apr 10, 2023
vanguard group inc
10.92%
7,047,477
SC 13G/A
Apr 06, 2023
blackrock inc.
14.3%
9,206,880
SC 13G/A
Feb 13, 2023
capital world investors
7.7%
4,978,524
SC 13G/A

Recent SEC filings of Tandem Diabetes Care Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
May 31, 2024
SD
SD
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading

Peers (Alternatives to Tandem Diabetes Care Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.0B
40.3B
-0.56% 0.17%
31.97
4.46
-2.84% -3.00%
67.0B
19.7B
-1.30% -8.44%
50.29
3.4
4.82% -17.56%
20.4B
3.9B
-2.39% -15.83%
44.18
5.21
5.72% 46.72%
17.2B
14.9B
-4.28% -22.37%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.42% 26.61%
30.89
2.73
6.16% 35.06%
8.5B
12.4B
-8.96% -11.44%
21.87
0.68
-0.93% -18.83%
8.0B
2.6B
-4.13% -24.00%
-24.93
3.09
-6.25% -68.58%
5.5B
3.9B
-5.09% -29.87%
-58.05
1.41
0.23% 90.80%
3.4B
387.1M
-0.21% 32.29%
-215.63
8.87
30.82% 65.57%
2.0B
6.6B
-10.10% -15.73%
10.59
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
18.01% 16.23%
-2.22
0.48
7.94% -1695.32%
385.1M
169.3M
1.48% -3.53%
-5.01
2.28
7.49% -244.90%
249.1M
324.0M
0.65% -42.87%
-1.3
0.77
-3.19% -337.41%
50.6M
50.5M
3.55% -78.84%
-2.22
1
14.25% -10.06%
1.8M
3.7M
-17.65% -79.41%
-0.15
0.48
5.77% 8.23%

Tandem Diabetes Care Inc News

Latest updates
MarketBeat23 hours ago

Tandem Diabetes Care Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-2.6%191,674196,796185,622195,917169,383220,502204,547200,262175,907209,996179,627172,139141,037168,065123,603109,23697,926108,39894,65793,25565,995
Gross Profit1.5%94,67293,29589,753101,73582,907115,523104,425101,94691,093113,72996,74592,45473,28790,55665,31354,39050,26160,27250,68349,90433,353
Operating Expenses6.2%136,350128,355121,298140,543210,724133,300151,918114,185106,431100,99189,02587,02276,52471,89466,32266,42763,83458,12856,68751,76944,350
  S&GA Expenses5.1%90,10685,75179,32897,61089,81497,69284,10480,61473,27171,49964,92366,52358,56354,51850,22850,44049,71745,56144,64940,56534,961
  R&D Expenses--------33,57133,16029,49224,10220,49917,96117,37616,09415,98714,11712,56812,03811,2049,389
EBITDA Margin44.3%-0.15*-0.27*-0.24*-0.26*-0.23*-0.10*-0.06*0.01*0.03*0.05*0.06*0.04*---------
Interest Expenses------2,157---2,157-----------
Income Taxes344.6%3,200-1,3082,2321,146287-2591,6002,100-1,70032954.0061.00-10032.0039.00-2,10098.0077.0072.00--
Earnings Before Taxes-26.1%-39,500-31,324-30,700-34,629-123,586-16,132-47,300-13,000-16,43911,1325,8004,100-5,16117,059-9,400-29,182-14,8002,729-2,829-1,512-
EBT Margin40.0%-0.18*-0.29*-0.27*-0.28*-0.25*-0.12*-0.08*-0.02*0.01*0.02*0.03*0.01*---------
Net Income-42.4%-42,715-30,002-32,961-35,775-123,873-15,852-48,970-15,056-14,71510,8085,7944,008-5,04417,000-9,408-27,107-14,8672,652-2,901-1,512-22,992
Net Income Margin38.3%-0.18*-0.30*-0.27*-0.28*-0.26*-0.12*-0.09*-0.02*0.01*0.02*0.03*0.01*---------
Free Cashflow-0.3%-12,453-12,415-5,345-13,700-27,15419310,233-5,21611,15713,88931,04927,080---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.2%9419539409479541,0531,0481,0371,015905850795754716673616343326293255215
  Current Assets-1.7%735748758764758850834835818812755698662637592540281276247213186
    Cash Equivalents0.2%59.0059.0080.0013112817312411594.0071.0011299.0012195.0012922274.0051.0046.0038.0040.00
  Inventory-2.6%15415814314813211110588.0080.0069.0066.0067.0067.0064.0071.0062.0060.0049.0041.0027.0023.00
  Net PPE1.3%78.0077.0076.0074.0075.0069.0073.0059.0050.0050.0050.0049.0050.0050.0049.0044.0038.0033.0028.0023.0017.00
Liabilities9.2%69863962661761561362658757847246144944135034634913613112611094.00
  Current Liabilities-1.2%19319518717517116517413913213212010910310410611410099.0010084.0077.00
  Long Term Debt21.9%347285285284284283283282282281281281280203199195-----
    LT Debt, Non Current21.9%347285285284284283283282282281281281280203199195-----
Shareholder's Equity-22.5%243314314329339440422450437433390346313366327268207195167145121
  Retained Earnings-4.5%-994-951-921-888-853-729-713-664-649-634-645-651-655-659-676-666-639-624-627-624-623
  Additional Paid-In Capital-2.0%1,2381,2641,2381,2191,1921,1711,1401,1181,0901,0681,0359979681,0251,003934847820794770744
Accumulated Depreciation-100.0%-53.00---56.00---49.00---39.00---30.00---
Shares Outstanding-1.5%65.0066.0065.0065.0065.0065.0064.0064.0064.0063.0063.0063.00---------
Float----1,600---3,800-------5,400---3,600-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-10.8%-7,996-7,21655.00-6,323-18,3265,82023,9436,90113,80019,63534,14428,89528,68515,23714,56415,499-20,63119,44323,0193,568-4,124
  Share Based Compensation-3.1%22,03922,74120,74123,40021,19424,44122,23620,13118,11017,09915,72914,97712,94713,30812,83716,42115,86518,68517,23012,3229,834
Cashflow From Investing69.5%-5,056-16,584-48,5255,698-26,32935,777-14,1636,3575,197-76,818-39,203-64,761-6,094-59,626-137,825-131,52132,916-20,901-22,171-14,661778
Cashflow From Financing419.1%13,5862,617-1,9113,948-5416,100-7748,0513,50015,88618,85013,6233,5739,20429,931263,82211,4816,4187,0348,7931,962
  Buy Backs-30,000--------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TNDM Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Sales$ 191,674$ 169,383
Cost of sales97,00286,476
Gross profit94,67282,907
Operating expenses:  
Selling, general and administrative90,10689,814
Research and development46,24442,160
Acquired in-process research and development expenses078,750
Total operating expenses136,350210,724
Operating loss(41,678)(127,817)
Other income (expense), net:  
Interest income and other, net5,3145,865
Interest expense(1,897)(1,634)
Loss on extinguishment of debt(1,268)0
Total other income (expense), net2,1494,231
Loss before income taxes(39,529)(123,586)
Income tax expense3,186287
Net loss(42,715)(123,873)
Other comprehensive income (loss):  
Unrealized gain (loss) on short-term investments(1,296)1,749
Foreign currency translation losses(1,008)(25)
Comprehensive loss$ (45,019)$ (122,149)
Net loss per share - basic (in dollars per share)$ (0.65)$ (1.92)
Net loss per share - diluted (in dollars per share)$ (0.65)$ (1.92)
Weighted average shares used to compute basic net loss per share (in shares)65,32664,549
Weighted average shares used to compute diluted net loss per share (in shares)65,32664,549

TNDM Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 58,979$ 58,868
Short-term investments408,831409,044
Accounts receivable, net92,965105,555
Inventories153,893157,937
Prepaid and other current assets20,52516,585
Total current assets735,193747,989
Property and equipment, net77,53076,542
Operating lease right-of-use assets88,28687,791
Other long-term assets40,03640,336
Total assets941,045952,658
Current liabilities:  
Accounts payable48,14349,586
Accrued expenses10,93212,726
Employee-related liabilities41,67643,430
Operating lease liabilities17,32017,060
Deferred revenue44,56243,994
Other current liabilities30,33828,462
Total current liabilities192,971195,258
Convertible senior notes, net - long-term347,497285,035
Operating lease liabilities - long-term112,732113,572
Deferred revenue - long-term12,29913,331
Other long-term liabilities32,48231,830
Total liabilities697,981639,026
Commitments and contingencies (Note 13)00
Stockholders’ equity:  
Common stock, $0.001 par value; 200,000 shares authorized, 64,563 and 65,552 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.6566
Additional paid-in capital1,238,4491,263,997
Accumulated other comprehensive income (loss)(935)1,369
Accumulated deficit(994,515)(951,800)
Total stockholders’ equity243,064313,632
Total liabilities and stockholders’ equity$ 941,045$ 952,658
TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
 CEO
 WEBSITEtandemdiabetes.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES2600

Tandem Diabetes Care Inc Frequently Asked Questions


What is the ticker symbol for Tandem Diabetes Care Inc? What does TNDM stand for in stocks?

TNDM is the stock ticker symbol of Tandem Diabetes Care Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tandem Diabetes Care Inc (TNDM)?

As of Thu Jun 13 2024, market cap of Tandem Diabetes Care Inc is 2.94 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNDM stock?

You can check TNDM's fair value in chart for subscribers.

What is the fair value of TNDM stock?

You can check TNDM's fair value in chart for subscribers. The fair value of Tandem Diabetes Care Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tandem Diabetes Care Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNDM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tandem Diabetes Care Inc a good stock to buy?

The fair value guage provides a quick view whether TNDM is over valued or under valued. Whether Tandem Diabetes Care Inc is cheap or expensive depends on the assumptions which impact Tandem Diabetes Care Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNDM.

What is Tandem Diabetes Care Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, TNDM's PE ratio (Price to Earnings) is -20.75 and Price to Sales (PS) ratio is 3.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNDM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tandem Diabetes Care Inc's stock?

In the past 10 years, Tandem Diabetes Care Inc has provided -0.119 (multiply by 100 for percentage) rate of return.